Q2 2025 Omeros Corp Earnings Call Transcript
Key Points
- Omeros Corp (OMER) has successfully negotiated an exchange agreement to extend the maturity of its convertible notes from 2026 to 2029, reducing near-term debt obligations by over $100 million.
- The company has an active at-the-market facility with the capacity to raise up to $150 million, providing flexibility to access additional capital.
- The FDA has accepted the resubmitted Biologics License Application for narsoplimab in TA-TMA, with a target action date set for September 25.
- Omeros Corp (OMER) is well-prepared for the potential launch of narsoplimab, having identified key transplant centers and engaged with payers to ensure patient access.
- The company is advancing its pipeline with ongoing clinical trials for zaltenibart in PNH and OMS527 for cocaine use disorder, supported by a grant from the National Institute on Drug Abuse.
- Omeros Corp (OMER) reported a net loss of $33.5 million for the first quarter of 2025, an increase from the previous quarter.
- The company has suspended its Expanded Access Program for narsoplimab, affecting patients who lack approved treatment options for TA-TMA.
- There is a temporary pause on the Phase 3 program for zaltenibart in PNH due to capital considerations, potentially delaying its development timeline.
- OMIDRIA royalties decreased significantly in the first quarter of 2025 compared to the previous quarter, impacting revenue.
- Interest expense increased in the first quarter, driven by changes in the OMIDRIA royalty obligation and new convertible notes.
Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are on a listen-only mode. After the company's remarks, we will conduct a question-and-answer session. Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website for one week from today.
I'll turn the call over to Jennifer Williams, Investor Relations for Omeros.
Good afternoon, and thank you for joining the call today. I'd like to remind you that some of the statements that will be made on the call today will be forward-looking. These statements are based on management's beliefs and expectations as of today only and are subject to change. All forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially. Please refer to the special notes in the Risk Factors section regarding forward-looking statements and the company's quarterly report on Form 10-Q,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
